Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection

Pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor that has been approved for treatment of a wide variety of malignancies. Immune-mediated colitis is a known but uncommon adverse effect of pembrolizumab. Symptoms of immune-mediated colitis can be similar to those of many other gastroint...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Cheng, Klionsky, Yael, Treasure, Michelle E., Bruno, Debora S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477466/
https://www.ncbi.nlm.nih.gov/pubmed/31043955
http://dx.doi.org/10.1159/000497155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477466/
https://www.ncbi.nlm.nih.gov/pubmed/31043955
http://dx.doi.org/10.1159/000497155

Ejemplares similares